Skip to main content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Apply for the Alliance

This image shows ultra-stable RNA nanoparticles (red color) that have resourceful functionalities. They can self-assemble from RNA fragments carrying therapeutic RNAs and receptor targeting RNA aptamers.

Credit: National Cancer Institute

Apply for Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01)

The NCI Alliance for Nanotechnology in Cancer is accepting applications for the Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01) initiative. The first receipt date for this Funding Opportunity Announcement (FOA) initiative, PAR-20-116 (, is May 21, 2020. The FOA will include three more receipt dates through November 18, 2021. The FOA will not allow for clinical trial funding. Please see key dates in the FOA listed.

This FOA is to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. Proposed TTNCI projects should be designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs. Research priorities of the proposed program were selected based on clinical challenges where nanotechnology has displayed a unique potential solution, as compared to other contemporary approaches. These priority areas include: 1) Combination Therapy, 2) Immunotherapy, and 3) Imaging and Diagnostics.

Apply for Innovative Research in Cancer Nanotechnology R01

The NCI Alliance for Nanotechnology in Cancer is accepting applications for the Innovative Research in Cancer Nanotechnology (IRCN) (R01) initiative. The first receipt date for the current Funding Opportunity Announcement (FOA) for this initiative, PAR-17-240 (, is November 21, 2017. The FOA will include five more receipt dates through May 21, 2020.  Please see key dates in the FOA listed.

This FOA will solicit applications for the development of innovative research projects addressing major barriers in cancer biology and/or oncology using nanotechnology and emphasizing fundamental understanding of nanomaterial interactions with biological systems, mechanisms of nanoparticle delivery in vivo, and characterization of diagnostic devices in vitro.

Among the areas of research encouraged in this initiative are: studies towards fundamental understanding of nanomaterial and / or nanodevice interactions with biological systems, mechanisms of delivery of nanoparticles and / or nanodevices to desired and intended cancer targets in vivo, and characterization of detection and diagnostic devices in vitro.

Cancer nanotechnology expertise and/or collaborative investigations combining expertise in cancer biology, oncology, chemistry, physics, and materials science will be encouraged and these investigators should consider applying for this new FOA. Awardees will be part of the Alliance network, which also include the Centers of Cancer Nanotechnology Excellence, Cancer Nanotechnology Research Training Programs, and the Nanotechnology Characterization Laboratory. For more information about IRCNs, and the IRCN application and review, please see the PDF guidance for the IRCN initiative.

Apply for Cancer Nanotechnology Training Center T32 Grant

The Nanodelivery Systems and Devices Branch no longer supports cancer nanotechnology training center through the R25T mechanism.  Instead, prospective Cancer Nanotechnology Training Center applicants should seek their funding support under the T32 mechanism.  The Ruth L. Kirschstein National Research Service Award (NRSA) (T32) supports grants to institutions to develop or enhance research training opportunities for pre and postdoctoral fellow to be trained in cancer research, including nanotechnology-focused activities.  Applicants should submit their proposals in response to the Parent T32 program announcement. All NCI T32 applications are evaluated by Subcommittee F convened by the Division of Extramural Activities of the NCI.  See information about NCI’s T32 program.   For general information regarding policies and guidance in preparing an application for the T32 award, contact Dr. Susan Lim.

  • Updated: